One patent currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Sep 2043. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Sep 2043
Next term end
1
Patent families
When these terms end
Each bar runs from grant to computed term end. 2026 to 2043.20302034203820422043
26 pending applications: term is not computable until grant.Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Humanized CD19 Antibody and Use Thereof | 1 in force | to Sep 2043 |
Patents held now
Soonest term end first.
Showing 1 to 1 of 1
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,760,098 | Humanized CD19 Antibody and Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 1: 26 applications pending · 1 application abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.